INTRODUCTION
============

End-stage renal disease (ESRD) and chronic liver disease are serious and common medical problems worldwide. As the prevalence of ESRD and liver cirrhosis (LC) increase, physicians are likely to be faced with both of these diseases in one patient. The prevalence and incidence of ESRD have been increasing annually worldwide \[[@b1-kjim-2014-328],[@b2-kjim-2014-328]\], based on the growth of the number of patients with diabetes or hypertension. Patients with ESRD are at higher risk of viral hepatitis than are patients among the general population \[[@b3-kjim-2014-328],[@b4-kjim-2014-328]\]. The risk of progression to chronic conditions, such as LC and hepatocellular carcinoma, is also higher in these patients than in healthy individuals \[[@b4-kjim-2014-328]\].

The main causes of LC in more developed countries are hepatitis C virus (HCV) infection, alcohol consumption, and, increasingly, nonalcoholic liver disease. Hepatitis B virus (HBV) infection is the most common cause in sub-Saharan Africa and most parts of Asia. Korea is an endemic area for HBV infection, and the incidence of HBV-related LC is high. Moreover, the increase in the incidence of HCV infection secondary to an increase in the numbers of young drug and alcohol abusers in changing socioeconomic environments emphasizes the clinical importance of LC \[[@b5-kjim-2014-328]\]. The prevalence of patients with combined ESRD and cirrhosis is not well known, but 6.2% of patients with ESRD reportedly had LC when beginning renal replacement therapy in a national cohort study in Taiwan \[[@b6-kjim-2014-328]\]. LC is an increasingly more frequent cause of morbidity and mortality in more developed countries, being the 14th most common cause of death worldwide but the 4th most common in central Europe \[[@b7-kjim-2014-328],[@b8-kjim-2014-328]\]. The long-term outcome of LC is associated with complications of liver failure; additionally, renal failure has been identified as a prognostic factor and is associated with high mortality \[[@b9-kjim-2014-328]\].

Although the combined presence of LC and ESRD is clinically important, few studies have compared mortality between patients with and without cirrhosis \[[@b6-kjim-2014-328],[@b10-kjim-2014-328]\], and the optimum modalities of renal replacement therapy for patients with LC remain controversial \[[@b6-kjim-2014-328],[@b11-kjim-2014-328],[@b12-kjim-2014-328]\]. Therefore, the aim of this study was to investigate the association between LC and mortality among patients with ESRD and compare mortality between two dialysis modalities.

METHODS
=======

Study population
----------------

From January 2000 to December 2011, we enrolled patients who began dialysis therapy for ESRD at the Gachon University Gil Medical Center, Korea. Patients were excluded if they had recovered renal function or were younger than 18 years of age. We also excluded those who had undergone renal transplantation during the follow-up period or had incomplete medical records.

All patients' medical records were retrospectively reviewed with respect to age, sex, cause of ESRD, laboratory data, and comorbid conditions at the time of initiation of dialysis. The comorbid conditions included diabetes, cardiovascular disease, chronic obstructive pulmonary disease, systemic vasculitis, dementia, and cancer. We also collected information on the hepatitis serology and liver imaging results of patients with hepatitis. The diagnosis of LC was based on a combination of clinical conditions, such as hepatic encephalopathy, esophageal and gastric varix, and ascites as well as biochemical and radiographic criteria. The causes of LC were evaluated and included HBV or HCV infection, alcoholic liver disease, and other liver diseases. The severity of LC was assessed according to the Child-Pugh classification \[[@b13-kjim-2014-328]\], which considers serum bilirubin, albumin, prothrombin time, ascites, hepatic encephalopathy; patients were designated as class A if the total score was 5 or 6, class B if the score was 7 to 9, and class C if the score was 10 or higher. Liver-related death was defined as death associated with LC or its complications, such as esophageal and gastric varices, spontaneous bacterial peritonitis, hepatic failure, and primary liver cancer. Death not directly related to LC was classified as non-liver related death.

The patients were followed from the initiation of dialysis until the end of the study (December 2011) or death. Patients on dialysis during the follow-up period were censored on the date of loss to follow-up. This study was approved by the Institutional Review Board of Gachon University Gil Medical Center. The requirement for informed consent was waived by the board.

Statistical analyses
--------------------

Data are presented as mean ± standard deviation or numbers (%). Categorical data are expressed as frequency (%). The Kolmogorov-Smirnov test was used to analyze the normality of the distribution of the parameters measured. Comparisons between the two groups were made by Student *t* test and the chi-square test. Skewed data were analyzed with the Mann-Whitney *U* test and Fisher exact test. Mortality was determined using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis was used to assess the risk factors for mortality. Associations are presented as hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs). All statistical analyses were performed with SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). A value of *p* \< 0.05 was considered to indicate statistical significance.

RESULTS
=======

Patients' characteristics
-------------------------

Demographic and laboratory data are listed in [Table 1](#t1-kjim-2014-328){ref-type="table"}. We analyzed 1,069 patients with ESRD; of these, 742 were undergoing hemodialysis (HD) and 327 were undergoing peritoneal dialysis (PD). The prevalence of LC was 44 of the 1,069 patients (4.1%). The LC group was more likely to be younger and male compared with the non-LC group. Cirrhotic patients had a significantly higher prevalence of HBV infection, which was a major cause of LC. Cirrhotic patients had a significantly lower serum albumin level, but other laboratory data showed no difference between the LC and non-LC groups. There were no significant differences in the causes of ESRD, the dialysis modality, or the baseline comorbidities.

Liver cirrhosis and mortality in patients with ESRD
---------------------------------------------------

During the follow-up period, 213 patients (19.9%) died. The mean follow-up duration of all patients was 38.0 ± 33.6 months (interquartile range, 10 to 56). The mean follow-up time alive on dialysis in the LC group was 35.0 ± 32.7 months, and that in the non-LC group was 38.0 ± 33.7 months. The cumulative 1-, 3-, and 5-year survival rates of all patients were 93%, 82%, and 72%, respectively. Patients with concurrent ESRD and LC had a higher mortality rate than did patients with ESRD without LC (*p* = 0.011). The cumulative 1-, 3-, and 5-year survival rates of noncirrhotic patients were 93%, 83%, and 73%, respectively. The cumulative 1-, 3-, and 5-year survival rates of cirrhotic patients were 90%, 68%, and 48%, respectively ([Fig. 1](#f1-kjim-2014-328){ref-type="fig"}). Cirrhotic patients had higher liver-related mortality than that of noncirrhotic patients. The most common causes of death in the LC group were liver-related and cardiovascular. However, the most common causes of death in the non-LC group were cardiovascular and infection ([Table 2](#t2-kjim-2014-328){ref-type="table"}).

We used Cox proportional regression analyses to evaluate the possible risk factors for all-cause mortality. Univariate analysis demonstrated that LC was associated with mortality (HR, 1.956; 95% CI, 1.157 to 3.307; *p* = 0.011). Age, diabetes, cardiovascular disease, serum albumin of \< 3.5 mg/dL, total bilirubin, and the international normalized ratio (INR) were also associated with mortality ([Table 3](#t3-kjim-2014-328){ref-type="table"}). Multivariate Cox proportional hazards analyses revealed that LC remained a significant predictor of mortality even after adjustments for age (model 1: HR, 2.595; 95% CI, 1.524 to 4.420; *p* \< 0.001); age, albumin of \< 3.5 mg/dL, and INR (model 2: HR, 2.218; 95% CI, 1.278 to 3.848; *p* = 0.005); age, diabetes, and cardiovascular disease (model 3: HR, 2.703; 95% CI, 1.585 to 4.609; *p* \< 0.001); and age, albumin of \< 3.5 mg/dL, INR, total bilirubin, diabetes, and cardiovascular disease (model 4: HR, 2.172; 95% CI, 1.225 to 3.851; *p* = 0.008) ([Table 4](#t4-kjim-2014-328){ref-type="table"}).

Risk factors for mortality in cirrhotic patients with ESRD
----------------------------------------------------------

The causes of LC were HBV infection (75.0%), HCV infection (2.2%), alcohol consumption (11.4%), and HBV infection combined with alcohol consumption (11.4%). In total, 21 patients were classified as Child class A, 16 as class B, and 7 as class C. Esophageal or gastric varices were found in six patients (13.6%), ascites was found in 12 patients (27.3%), and hepatic encephalopathy was found in six patients (13.6%). The initial dialysis modalities were HD in 33 patients and PD in 11 patients. The prevalence of LC was 4.4% and 3.6% in the HD and PD groups, respectively. No significant differences were observed in the baseline characteristics of cirrhotic patients based on dialysis modality ([Table 5](#t5-kjim-2014-328){ref-type="table"}).

We used Cox proportional regression analyses to evaluate possible risk factors for all-cause mortality in cirrhotic patients with ESRD. The univariate analysis demonstrated that total bilirubin (HR, 6.246; 95% CI, 2.078 to 18.775; *p* = 0.001), Child-Pugh classification (HR, 2.362; 95% CI, 1.187 to 4.700; *p* = 0.014), and diabetes (HR, 3.496; 95% CI, 1.022 to 11.961; *p* = 0.046) were associated with mortality. No significant difference in survival was observed according to dialysis modality in cirrhotic patients ([Fig. 2](#f2-kjim-2014-328){ref-type="fig"}). After adjusting for confounding variables, total bilirubin (HR, 9.139; 95% CI, 2.054 to 40.659; *p* = 0.004) and diabetes (HR, 5.531; 95% CI, 1.201 to 25.473; *p* = 0.028) were significant risk factors for mortality in patients with ESRD and LC.

DISCUSSION
==========

This study investigated the long-term survival, and mortality risk of LC among patients undergoing dialysis and the effect of dialysis modality on the outcome of cirrhotic patients. We showed that patients with concurrent ESRD and LC had a significantly lower survival rate than did noncirrhotic patients, and LC was an independent predictor of mortality. There was no significant survival difference between HD and PD in cirrhotic patients.

In our study, the prevalence of LC in patients with ESRD was 4.1%. The prevalence of cirrhosis among patients with ESRD is not well known, but 4% to 6% of patients with ESRD have been found to have LC when beginning renal replacement therapy \[[@b6-kjim-2014-328],[@b10-kjim-2014-328],[@b14-kjim-2014-328]\]. The main cause of liver disease is viral hepatitis. The Asia-Pacific area is highly endemic for viral hepatitis infection among patients undergoing dialysis \[[@b15-kjim-2014-328]\], but the prevalence of viral hepatitis differs according to the geographical area. Korea is an endemic area for HBV infection, while Taiwan is an endemic area for HCV infection. Approximately 4.4% of patients undergoing HD and 3.6% of those undergoing PD have LC. Patients undergoing HD have a higher rate of LC than those undergoing PD. As shown by our results, many more patients undergoing HD than PD had LC in a national cohort study in Taiwan (6.2% vs. 5.3%, respectively) \[[@b6-kjim-2014-328]\].

Of the patients with ESRD, those with cirrhosis had poorer survival than those without cirrhosis. Cirrhosis is an increasingly frequent cause of morbidity and mortality. LC was an important predictor of mortality in patients undergoing dialysis in a cohort study in Taiwan \[[@b6-kjim-2014-328]\]. No laboratory data were evaluated in that study. Comorbidities such as diabetes and cardiovascular disease were identified as risk factors of mortality in patients with ESRD. The mortality of cirrhotic patients with ESRD was confounded by these comorbid conditions. In our study, univariate analysis showed that laboratory values, such as serum albumin of \< 3.5 mg/dL, total bilirubin, and INR, were associated with mortality. Therefore, we adjusted for not only comorbidities such as diabetes and cardiovascular disease, but also laboratory values such as albumin, total bilirubin, and INR. After adjustment, LC was an independent risk factor for death in patients with ESRD. The cirrhotic patients had higher liver-related mortality than that of noncirrhotic patients.

The outcome of patients with cirrhosis is associated with the severity and complications of liver failure \[[@b16-kjim-2014-328]\]. The most common prognostic variable in patients with cirrhosis was the Child-Pugh classification or its components (albumin, bilirubin, ascites, encephalopathy, and prothrombin time) \[[@b16-kjim-2014-328]\]. In our study, total bilirubin was related with mortality in cirrhotic patients with ESRD. Child-Pugh classification was associated with survival in the univariate analysis, but was not associated with survival after adjustment. De Vecchi et al. \[[@b17-kjim-2014-328]\] also showed no relationship between survival and Child-Pugh classification in cirrhotic patients undergoing PD. This discrepancy may be explained by the small number of patients. One study showed that diabetes is an independent prognostic factor in patients with cirrhosis \[[@b18-kjim-2014-328],[@b19-kjim-2014-328]\]. This finding is consistent with our results, although the characteristics of the study populations were different.

The most optimal renal replacement therapy for patients with ESRD and concomitant LC remains controversial. We analyzed the effect of dialysis modality on the outcome of cirrhotic patients with ESRD. Our data showed no significant difference in the outcome of LC in patients with ESRD between those undergoing HD and PD. Chien et al. \[[@b6-kjim-2014-328]\] reported no significant difference in survival time according to dialysis modality in patients with ESRD and preexisting LC. In their study, patients undergoing PD had a better crude survival rate than did patients undergoing HD. Compared with patients undergoing HD, those undergoing PD were younger and less likely to have comorbidities. After adjustment, there was no significant difference in survival between the HD and PD groups. Kim et al. \[[@b20-kjim-2014-328]\] also showed no difference in mortality between cirrhotic patients with ESRD undergoing HD and PD.

The initial dialysis modality choice in patients with LC is difficult to determine. PD has several advantages over HD in patients with LC, as it reduces the risk of HBV and HCV transmission. PD is also hemodynamically more stable than HD in patients with LC because of slow and continuous solute clearance \[[@b21-kjim-2014-328]\]. Direct drainage of ascites via the peritoneal catheter controls the volume of ascites and avoids repeated paracentesis. In addition, PD avoids the need for anticoagulation therapy. Despite these benefits, there are several limitations to the application of PD in cirrhotic patients. The instillation of dialysate may increase the abdominal pressure, which might cause complications of leakage, hydrothorax, and inguinal hernia \[[@b10-kjim-2014-328]\]. To avoid severe abdominal distension, a reduced volume of dialysate may be used, but this could increase the risk of inadequate dialysis. Cirrhotic patients are susceptible to spontaneous bacterial peritonitis \[[@b22-kjim-2014-328]\]. Protein loss into the dialysate may worsen hypoalbuminemia and induce malnutrition in cirrhotic patients.

HD in patients with LC has several limitations. Because of the decreased peripheral vascular resistance and high circulating nitric oxide levels in these patients \[[@b23-kjim-2014-328]\], the effective arterial blood volume is unavoidably reduced. Cirrhotic patients have a spontaneous tendency to develop arterial hypotension during HD, which limits ultrafiltration and worsens ascites. The increased bleeding tendency due to alterations in clotting factors and platelet abnormalities in cirrhotic patients may also be problematic for those undergoing HD, particularly with arteriovenous access. Rapid osmotic and electrolyte shifts during intermittent HD may potentially aggravate hepatic encephalopathy \[[@b24-kjim-2014-328],[@b25-kjim-2014-328]\]. This study had several limitations. First, it was a single-center study, resulting in potential bias. Second, the number of cirrhotic patients was relatively small due to the low prevalence of LC in the dialysis population. Because the number of cirrhotic patients treated with PD is limited, it is difficult to compare outcomes between HD and PD in patients with concurrent ESRD and LC. Finally, there might be some residual confounding factors as in other observational studies; thus, we can show only an association between these risk factors and mortality, not causality.

In conclusion, of the patients with ESRD, cirrhotic patients had poorer survival than noncirrhotic patients. There is no significant survival difference between HD and PD in cirrhotic patients. The choice of modality for renal replacement therapy in cirrhotic patients should be individualized with consideration of conventional indications and complications of LC. Further larger-scale and multicenter studies are needed to elucidate the associations of various risk factors with outcomes and mortality rates in patients with concurrent ESRD and LC.

KEY MESSAGE
===========

1\. Of patients with end-stage renal disease (ESRD), cirrhotic patients had poorer survival than noncirrhotic patients.

2\. Survival of patients undergoing peritoneal dialysis was comparable with that of patients undergoing hemodialysis among patients with ESRD and concomitant liver cirrhosis.
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![All-cause mortality of noncirrhotic and cirrhotic patients with end-stage renal disease. Patients with liver cirrhosis (LC) had a higher mortality rate than those without LC (*p* = 0.011).](kjim-2014-328f1){#f1-kjim-2014-328}

![Survival of cirrhotic patients undergoing hemodialysis (HD) and peritoneal dialysis (PD). No difference in survival was observed according to dialysis modality in cirrhotic patients (*p* = 0.562).](kjim-2014-328f2){#f2-kjim-2014-328}

###### 

Characteristics of all patients

  Characteristic              Total (n = 1,069)   LC group (n = 44)   Non-LC group (n = 1,025)   *p* value
  --------------------------- ------------------- ------------------- -------------------------- -----------
  Age, yr                     55.0 ± 14.6         50.9 ± 10.7         55.2 ± 14.7                0.015
  Male sex                    599 (56.0)          34 (77.3)           565 (55.1)                 0.004
  Cause of ESRD                                                                                  0.181
   Diabetes                   599 (56.0)          21 (47.7)           578 (56.4)                 
   Hypertension               90 (8.4)            5 (11.4)            85 (8.3)                   
   Glomerulonephritis         79 (7.4)            6 (13.6)            73 (7.1)                   
   Others                     301 (28.2)          12 (27.3)           289 (28.2)                 
  Dialysis modality                                                                              0.411
   Hemodialysis               742 (69.4)          33 (75)             709 (69.2)                 
   Peritoneal dialysis        327 (30.6)          11 (25)             316 (30.8)                 
  HBsAg positive              81 (7.6)            38 (86.4)           43 (4.2)                   \< 0.001
  Anti-HCV positive           21 (2.0)            1 (2.3)             20 (2.0)                   0.880
  Baseline comorbidity                                                                           
   Diabetes                   626 (58.6)          26 (59.1)           600 (58.5)                 0.904
   Cardiovascular disease     367 (34.3)          10 (22.7)           357 (34.8)                 0.111
   COPD                       14 (1.3)            0                   14 (1.4)                   0.436
   Systemic vasculitis        14 (1.3)            0                   14 (1.4)                   0.453
   Dementia                   31 (2.9)            0                   31 (3.0)                   0.250
   Cancer                     28 (2.6)            3 (6.8)             25 (2.4)                   0.112
  Laboratory                                                                                     
   Hemoglobin, g/dL           8.4 ± 1.7           8.1 ± 1.5           8.4 ± 1.7                  0.244
   Creatinine, mg/dL          8.0 ± 4.0           8.0 ± 4.5           8.0 ± 4.0                  \> 0.999
   Total protein, g/dL        6.1 ± 0.9           6.2 ± 0.7           6.1 ± 0.9                  0.662
   Albumin, g/dL              3.2 ± 0.6           3.0 ± 0.5           3.3 ± 0.6                  0.020
   Total bilirubin, mg/dL     0.5 ± 0.5           0.6 ± 0.4           0.5 ± 0.5                  0.085
   AST, U/L                   30 ± 134            30 ± 19             30 ± 137                   0.971
   ALT, U/L                   24 ± 112            25 ± 19             24 ± 114                   0.427
   INR                        1.03 ± 0.25         1.10 ± 0.17         1.02 ± 0.25                0.057
   Total cholesterol, mg/dL   161 ± 46            149 ± 37            161 ± 47                   0.138
   Ca × P, mg^2^/dL^2^        43.2 ± 16.7         42.3 ± 16.6         43.2 ± 16.7                0.722

Values are presented as mean ± SD or number (%).

LC, liver cirrhosis; ESRD, end-stage renal disease; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; COPD, chronic obstructive pulmonary disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; Ca × P, calcium phosphorus product.

###### 

Causes of death

  Variable                             LC group (death = 16)   Non-LC group (death = 197)   *p* value
  ------------------------------------ ----------------------- ---------------------------- -----------
  Liver related                        4                       0                            \< 0.001
   Varix bleeding                      2                       0                            
   Hepatocellular carcinoma            1                       0                            
   Spontaneous bacterial peritonitis   1                       0                            
  Non-liver related                    8                       138                          0.158
   Cardiovascular disease              4                       62                           
   Infection                           1                       62                           
   Malignancy                          0                       1                            
   Others                              3                       13                           
  Unknown                              4                       59                           0.783

LC, liver cirrhosis.

###### 

Hazard ratios and 95% confidence intervals for mortality by univariate Cox proportional hazards analysis

  Variable                    HR      95% CI         *p* value
  --------------------------- ------- -------------- -----------
  Liver cirrhosis             1.956   1.157--3.307   0.011
  Age, yr                     1.043   1.032--1.054   \< 0.001
  Diabetes                    1.733   1.299--2.311   \< 0.001
  Cardiovascular disease      1.491   1.130--1.966   0.005
  Hemoglobin \< 10 g/dL       1.032   0.747--1.425   0.848
  Serum albumin \< 3.5 g/dL   1.733   1.281--2.344   \< 0.001
  Total bilirubin, mg/dL      1.299   1.079--1.565   0.006
  AST \> 40 U/L               1.330   0.819--2.160   0.249
  ALT \> 40 U/L               1.269   0.782--2.060   0.335
  INR                         2.098   1.451--3.034   \< 0.001

HR, hazard ratio; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio.

###### 

Hazard ratios and 95% confidence intervals for mortality by multivariate Cox proportional hazards analysis

  Variable                                                 Liver cirrhosis                  
  -------------------------------------------------------- ----------------- -------------- ----------
  Model 1^[a](#tfn1-kjim-2014-328){ref-type="table-fn"}^   2.595             1.524--4.420   \< 0.001
  Model 2^[b](#tfn2-kjim-2014-328){ref-type="table-fn"}^   2.218             1.278--3.848   0.005
  Model 3^[c](#tfn3-kjim-2014-328){ref-type="table-fn"}^   2.703             1.585--4.609   \< 0.001
  Model 4^[d](#tfn4-kjim-2014-328){ref-type="table-fn"}^   2.172             1.225--3.851   0.008

HR, hazard ratio; CI, confidence interval.

Adjusted for age.

Adjusted for age, albumin \< 3.5 g/dL, and the international normalized ratio (INR).

Adjusted for age, diabetes, and cardiovascular disease.

Adjusted for age, albumin \< 3.5 g/dL, INR, total bilirubin, diabetes, and cardiovascular disease.

###### 

Characteristics of the cirrhotic patients

  Characteristic                Total (n = 44)   Hemodialysis (n = 33)   Peritoneal dialysis (n = 11)   *p* value
  ----------------------------- ---------------- ----------------------- ------------------------------ -----------
  Age, yr                       50.9 ± 10.7      50.3 ± 11.4             52.6 ± 8.6                     0.541
  Male sex                      34 (77.3)        27 (81.8)               7 (63.6)                       0.237
  Diabetes                      26 (59.1)        20 (60.6)               6 (54.5)                       0.723
  Cardiovascular disease        10 (22.7)        7 (21.2)                3 (27.3)                       0.692
  Cause of liver cirrhosis                                                                              0.153
   HBV infection                33 (75)          25 (75.8)               8 (72.7)                       
   Alcohol                      5 (11.4)         5 (15.2)                0                              
   HCV infection                1 (2.2)          0                       1 (9.1)                        
   Alcohol and HBV infection    5 (11.4)         3 (9.1)                 2 (18.2)                       
  Child-Pugh class                                                                                      0.770
   A                            21 (47.7)        15 (45.5)               6 (54.5)                       
   B                            16 (36.4)        13 (39.4)               3 (27.3)                       
   C                            7 (15.9)         5 (15.1)                2 (18.2)                       
  Varix (esophageal, gastric)   6 (13.6)         6 (18.2)                0                              0.311
  Ascites                       12 (27.3)        11 (33.3)               1 (9.1)                        0.240
  Hepatic encephalopathy        6 (13.6)         6 (18.2)                0                              0.311
  Laboratory                                                                                            
   Hemoglobin, g/dL             8.1 ± 1.5        8.1 ± 1.5               8.4 ± 1.4                      0.522
   Creatinine, mg/dL            8.0 ± 4.5        8.2 ± 5.0               7.5 ± 2.8                      0.684
   Total protein, g/dL          6.2 ± 0.7        6.2 ± 0.7               6.2 ± 0.8                      0.864
   Albumin, g/dL                3.0 ± 0.5        3.0 ± 0.5               3.0 ± 0.7                      0.833
   Total bilirubin, mg/dL       0.6 ± 0.4        0.6 ± 0.4               0.6 ± 0.4                      0.963
   AST, U/L                     30 ± 19          30 ± 16                 34 ± 26                        0.557
   ALT, U/L                     25 ± 19          26 ± 19                 22 ± 23                        0.529
   INR                          1.10 ± 0.17      1.11 ± 0.18             1.06 ± 0.12                    0.410
   Total cholesterol, mg/dL     149 ± 37         147 ± 38                154 ± 36                       0.138
   Ca × P, mg^2^/dL^2^          42.3 ± 16.6      42.6 ± 15.0             41.2 ± 22.0                    0.813

Values are presented as mean ± SD or number (%).

HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; Ca × P, calcium phosphorus product.
